Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:f549:0:b0:441:282b:bd with SMTP id j9csp796192wrp; Thu, 30 Apr 2026 07:19:47 -0700 (PDT) X-Received: by 2002:a05:620a:258a:b0:8cd:b024:114d with SMTP id af79cd13be357-8fabb8c59c3mr325916185a.40.1777558787382; Thu, 30 Apr 2026 07:19:47 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1777558787; cv=none; d=google.com; s=arc-20240605; b=YVjSJdTz8goCRvt58kB/3vN7Q87lKUGzmUyaWfm4Gv/qdiwaWHtXGr6sG3j4FiCmK0 ID2INI/jwL/egzkvHPxp5NtKx2mqxgECvw11Y4A3/MNrieBFa1/4hKpDE4xUjrlOmHek UK5xNifZdm9C2mLDftIjssVRfgCYLUCCmygA/yDHfvS1QTsUAUgU1YIptKlc9PIjX2OD E9cuiozmdAOMWx4bFy7OgzLaqqXeJbBBGFTRSVI6qA1xabtBaPuUjzYDYf6P4plPmnP8 U8oQZLnWn2wLG4vqPQXNrUBhuV5qb68F7/cqj6g3jWwbyYleDxj3WcuzmZAV3TcrrOu5 VrSg== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=lVE8ruuRfLTt0TIbvDoaQSLjAgwmMtrzbrk8H7TgpYs=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=e/BL85eZs6tFVvSWge+OVxxW61TbUZHxXvf+uA+5ztU8aVOFNdjvEh5JLrsypPbRcw Z4++g16tlRgeKlBV47y8BPe60DRHT62/+G6SZAB3h9x1hB2nNXg+wDtZqCHzp35GpvnZ 32rwKdDHM2Yf2xX3+2ophHjsLxWD3zed39c62AqqAZBJ8ME2PkY1vvtu2KKCnlp25CH2 2HNWNuANW69hKGIy0EL5+2yPzYWj9rsRBrBBubBuCMiE7y9ByOIfkrlTKCtXieW1/3wa uE+PfJQQjGJa6n5bKLV7Lf7uApZMjOsFh5hnrxeij4D8SQHbGeC7WrRM17fdjUhHgVmF s1qA==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b="gM/E1XRx"; dkim=pass header.i=@mailgun.org header.s=mg header.b=h5RhxaHw; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.11 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v511.v5375b7fa.use4.send.mailgun.net (v511.v5375b7fa.use4.send.mailgun.net. [159.112.244.11]) by mx.google.com with UTF8SMTPS id af79cd13be357-8fb9f307815si3525385a.118.2026.04.30.07.19.47 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 30 Apr 2026 07:19:47 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.11 as permitted sender) client-ip=159.112.244.11; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b="gM/E1XRx"; dkim=pass header.i=@mailgun.org header.s=mg header.b=h5RhxaHw; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.11 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1777558787; x=1777565987; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=lVE8ruuRfLTt0TIbvDoaQSLjAgwmMtrzbrk8H7TgpYs=; b=gM/E1XRxYygxPAsFSxzYm2JHF+d2fa9pakWxF201q1bhzjcvx7oHHrmweLIoFizKX9amCYv69HwkvlVYh/w6bLEVfVwLbm3XhB0SIUWuUbymr8DCYGaH23eMtXYLHmmVoWKlYyYIBzgDqzZFOVJpWSJ9nY6LGOWELyiSCg+7+po= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1777558787; x=1777565987; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=lVE8ruuRfLTt0TIbvDoaQSLjAgwmMtrzbrk8H7TgpYs=; b=h5RhxaHwMt0Mu0fMJH/0SrVGOAvEc5/JHiBZSqj6hqREypNIGY/BcOs4eWAOfNfH3cHsix4NxkUqjBOrv286LoUoYUP7E4VFVj0a2RGLir+pppQNL2FqSXAhrUJb9TxKA8BkLGGMPjxZGT1sxQ/yVUu1NXtnzojDepII5NreGUw= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by f06a7b455627bc2133973b221569289fe087be4ee37938a3361bd61029a6bad6 with HTTP id 69f36502248a36f3e699f591; Thu, 30 Apr 2026 14:19:46 GMT X-Mailgun-Sending-Ip: 159.112.244.11 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="106b40a7b3a95666b3da58827db654c5b3602851c7c3f24c927d6d9aba99" Subject: New Study Worth Knowing About: GLP-1s and Alzheimer's From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260430141932.3.4d361568adcbcf41@mg-d0.substack.com> Date: Thu, 30 Apr 2026 14:19:32 +0000 Feedback-Id: post-196001517:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1777558784771", "is_freemail": "true", "post_audience": "everyone", "post_id": "196001517", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --106b40a7b3a95666b3da58827db654c5b3602851c7c3f24c927d6d9aba99 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/new-study-w= orth-knowing-about-glp A new research review just came out in Molecular and Cellular Neuroscience = (April 2026) looking at how GLP-1 drugs =E2=80=94 the same class as Ozempic= , Wegovy, Mounjaro, and Trulicity =E2=80=94 might affect Alzheimer=E2=80=99= s disease. ScienceAlert covered it, but I wanted to dig into the actual pap= er and break it down in plain English so anyone in the community can follow= along. Link to the study: https://doi.org/10.1016/j.mcn.2026.104091 [ https://subs= tack.com/redirect/7bf42a5d-3762-4f67-ab19-3d2b2893efef?j=3DeyJ1IjoiNGl3b2U2= In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ]=20 ScienceAlert summary: https://www.sciencealert.com/weight-loss-drugs-may-re= duce-buildup-of-alzheimers-proteins-major-review-finds [ https://substack.c= om/redirect/7afc43b6-816d-46b6-ac3f-b75058899314?j=3DeyJ1IjoiNGl3b2U2In0.sV= DxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] A Quick Primer on Alzheimer=E2=80=99s Alzheimer=E2=80=99s is defined by two specific things going wrong in the br= ain: Amyloid-beta plaques =E2=80=94 sticky gunk that builds up between your brai= n cells. Your body makes a protein called APP and chops it into small piece= s. In a healthy brain, those pieces get cleared out. In Alzheimer=E2=80=99s= , they clump together into hard plaques that physically block neurons from = communicating. Tau tangles =E2=80=94 tau is a protein that lives inside your neurons and a= cts like the support beams holding the cell=E2=80=99s internal scaffolding = together. In Alzheimer=E2=80=99s, tau gets chemically gunked up (a process = called =E2=80=9Chyperphosphorylation=E2=80=9D) and collapses into twisted t= angles inside the cell, which then dies. Plaques outside the cells, tangles inside the cells. Together they=E2=80=99= re considered the defining features of Alzheimer=E2=80=99s. Reduce either o= ne, and you=E2=80=99re theoretically slowing the disease. The reason this matters for the study: GLP-1 drugs appear to reduce both. What The Researchers Did A team out of Anglia Ruskin University in the UK did a systematic review = =E2=80=94 meaning they didn=E2=80=99t run a new experiment, they pulled tog= ether every quality study they could find on four specific GLP-1 drugs and = looked for patterns: Liraglutide (Saxenda, Victoza) Semaglutide (Ozempic, Wegovy) Exenatide (Byetta, Bydureon) Dulaglutide (Trulicity) They searched PubMed, Embase, and Cochrane Library =E2=80=94 the three majo= r medical research databases. They ended up with 30 preclinical studies (ce= lls in a dish and animal models) and 2 human clinical trials. The whole goal: do these drugs actually reduce amyloid plaques and tau tang= les? And if so, how? What They Found in Animal and Cell Studies This is where the data gets exciting: 22 out of 30 studies showed reductions in amyloid-beta plaques 19 out of 30 studies showed reductions in tau tangles That=E2=80=99s about 73% showing plaque reduction and 63% showing tangle re= duction. In research terms, that=E2=80=99s a strong, consistent signal =E2= =80=94 not a one-off finding. By drug: Liraglutide =E2=80=94 the most studied of the four. The most consistent. Re= duced both plaques AND tangles across multiple models. Dulaglutide =E2=80=94 fewer studies, but consistent. Reduced both plaques a= nd tangles, and improved cognitive performance in mice. Semaglutide =E2=80=94 mostly positive. Four studies showed reductions, one = showed no effect. Exenatide =E2=80=94 most mixed results. Some studies showed reductions, oth= ers showed nothing. Smallest overall effect. How Are GLP-1 Drugs Doing This? (The Mechanisms) This is the most important section. The researchers identified several path= ways through which these drugs appear to fight Alzheimer=E2=80=99s patholog= y. Walking through them simply: 1. They calm down brain inflammation Your brain has its own immune cells called microglia. When microglia get st= uck in =E2=80=9Calarm mode=E2=80=9D for too long, they pump out inflammator= y chemicals that actually increase the production of amyloid plaques. It=E2= =80=99s a vicious cycle =E2=80=94 inflammation makes plaques, plaques cause= more inflammation. GLP-1 drugs calm microglia down. Less inflammation means less plaque produc= tion at the source. 2. They fix insulin signaling in the brain There=E2=80=99s a reason researchers sometimes call Alzheimer=E2=80=99s =E2= =80=9CType 3 Diabetes.=E2=80=9D The Alzheimer=E2=80=99s brain shows insulin= resistance =E2=80=94 meaning brain cells can=E2=80=99t use sugar for energ= y properly. That metabolic dysfunction is directly tied to both plaque buil= dup and tangle formation. GLP-1 drugs were literally designed to fix insulin signaling. When they res= tore that function in brain cells, the brain gets better at clearing out to= xic protein waste. 3. They turn down the enzymes that make plaques Remember APP =E2=80=94 the protein that gets chopped up into amyloid fragme= nts? The enzymes doing the chopping are called secretases. GLP-1 drugs appe= ar to shift the balance away from the =E2=80=9Cbad=E2=80=9D cutting pattern= (which produces toxic plaque material) toward the =E2=80=9Csafe=E2=80=9D c= utting pattern (which produces harmless fragments). In other words, they reduce plaque production at the factory level. 4. They block the enzyme that creates tangles Tau gets converted into tangles by an enzyme called GSK-3=CE=B2. GLP-1 drug= s activate a signaling pathway (called PI3K/Akt) that inhibits GSK-3=CE=B2. Less GSK-3=CE=B2 activity =3D less tau gunking up =3D fewer tangles forming= inside neurons. 5. They help the brain clean itself out Your brain has its own waste-clearance system that flushes out toxic protei= ns. GLP-1 receptors are present on cells called astrocytes that sit around = brain blood vessels. When activated, they help move water through the brain= in a way that flushes amyloid out. Imagine cleaning a room =E2=80=94 these drugs aren=E2=80=99t just stopping = the mess from getting made, they=E2=80=99re also helping take the trash out= =2E 6. They help neurons survive in general GLP-1 activation increases brain growth factors like BDNF (think of it as f= ertilizer for neurons), reduces oxidative stress, supports the cell=E2=80= =99s energy production, and prevents premature cell death. This is the big-picture takeaway: these drugs aren=E2=80=99t doing one thin= g. They=E2=80=99re doing six things at once, all in the same direction. Tha= t=E2=80=99s a big deal because most failed Alzheimer=E2=80=99s drugs only t= argeted one mechanism. The Human Trial Data =E2=80=94 Being Honest Here This is where I have to slow the hype train down. The two human clinical tr= ials in the review were not nearly as impressive as the animal data: Liraglutide trial (26 weeks): No reduction in plaque burden No improvement in cognition Did preserve brain glucose metabolism (a sign neurons were still functionin= g) Exenatide trial (18 months): No significant changes in plaques or tangles in cerebrospinal fluid Did reduce amyloid-beta in extracellular vesicles (an early biomarker) No cognitive benefit So: the preclinical data is strong. The human cognitive data is not there y= et. My Analysis =E2=80=94 What This Actually Means A few honest takeaways: 1. Preclinical-to-human translation is the eternal Alzheimer=E2=80=99s prob= lem. The graveyard of Alzheimer=E2=80=99s drug development is full of compo= unds that worked beautifully in mice and failed in humans. Mouse models are= typically genetically engineered to develop pathology fast =E2=80=94 which= doesn=E2=80=99t fully mirror what happens in a human brain over decades. 2. The lead author=E2=80=99s framing is the right one =E2=80=94 prevention,= not treatment. The researchers explicitly say these drugs may work as a pr= eventative, not as a treatment for people who already have established cogn= itive impairment. That tracks with the human trial data =E2=80=94 those tri= als enrolled people who already had Alzheimer=E2=80=99s. By that point, you= may simply be too late. 3. The multi-mechanism story is genuinely promising. Past Alzheimer=E2=80= =99s drugs failed because they targeted one pathway. GLP-1 drugs hit six at= once. That=E2=80=99s a structurally better bet. 4. There=E2=80=99s a confounder nobody can fully solve yet. GLP-1 drugs tre= at obesity and Type 2 diabetes =E2=80=94 two of the biggest modifiable risk= factors for dementia. So are these drugs protecting the brain directly, or= are they protecting the brain by treating systemic metabolic disease that = would otherwise damage the brain? Probably both. The proportions matter for= figuring out who actually benefits most. 5. This review only covers the older GLP-1 drugs. Tirzepatide (GLP-1 + GIP)= and retatrutide (GLP-1 + GIP + glucagon) aren=E2=80=99t in this analysis. = Whether the dual and triple agonists carry a similar =E2=80=94 or stronger = =E2=80=94 neuroprotective signal is still an open question. 6. The peptide research community has parallel tools worth knowing. Compoun= ds like Cerebrolysin, Semax, Selank, and the bioregulators are working on o= verlapping mechanisms (inflammation, neurotrophic support, neuronal surviva= l) through different pathways. The multi-mechanism neuroprotection theme is= n=E2=80=99t unique to GLP-1 drugs =E2=80=94 it=E2=80=99s where the entire f= ield is heading. Bottom Line This review pulls together strong preclinical evidence that GLP-1 receptor = agonists reduce both amyloid plaques and tau tangles through multiple mecha= nisms =E2=80=94 inflammation, insulin signaling, enzyme regulation, brain c= learance, and neuroprotection. The signal is consistent and biologically co= herent. Human cognitive data isn=E2=80=99t there yet, but that=E2=80=99s likely bec= ause the trials enrolled people too late in the disease. The next wave of t= rials needs to recruit at-risk people before symptoms start =E2=80=94 that= =E2=80=99s where the real test happens. This is one more data point worth tracking as the field develops. Stay meas= ured, watch the next 2-3 years of trial readouts, and don=E2=80=99t get ahe= ad of the evidence. Drop questions or thoughts below. Disclaimer: This content is for research and educational purposes only and = is not medical advice. All compounds discussed (peptides, GLP-1 receptor ag= onists, and related research chemicals) are referenced in the context of re= search use only (RUO) and the published scientific literature. Nothing in t= his post should be interpreted as a recommendation for human consumption, d= iagnosis, prevention, or treatment of any disease or condition. Always cons= ult a qualified healthcare professional for medical decisions. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOakF3TVRVeE55d2lhV0YwSWpveE56YzNOV= FU0TnpnMExDSmxlSEFpT2pFNE1Ea3dPVFEzT0RRc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LjB4dDBOX1RkdlJwQTBpUlJrRTh6SzBrbmh= YMXVhQTZyUzJXcU1MWjRhWUEiLCJwIjoxOTYwMDE1MTcsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc3NTU4Nzg0LCJleHAiOjIwOTMxMzQ3ODQsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.uC-IDEHOyB1wbDVWSqMBupWJqtgNQ5XbENxhZMI= jDec? --106b40a7b3a95666b3da58827db654c5b3602851c7c3f24c927d6d9aba99 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = New Study Worth Knowing About: GLP-1s and Alzheimer's=3D""
A new research review just came out in Molecul= ar and Cellular Neuroscience (April 2026) looking at how GLP-1 drugs —= ; the same class as Ozempic, Wegovy, Mounjaro, and Trulicity — might = affect Alzheimer’s disease.
͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­
=
 
<= tr>=
3D""
3D""
<= table role=3D"presentation" width=3D"38" border=3D"0" cellspacing=3D"0" cel= lpadding=3D"0">
3D""
=
3D""
READ IN A= PP3D""
 

A new research review just came out in Molecular and Cell= ular Neuroscience (April 2026) looking at how GLP-1 drugs —= ; the same class as Ozempic, Wegovy, Mounjaro, and Trulicity — might = affect Alzheimer’s disease. ScienceAlert covered it, but I wanted to = dig into the actual paper and break it down in plain English so anyone in t= he community can follow along.

=
3D""=
<= /div>

Link to the study: https://doi.org/10.1016/j.mcn.2026.10= 4091

ScienceAlert summary: https://www.sc= iencealert.com/weight-loss-drugs-may-reduce-buildup-of-alzheimers-proteins-= major-review-finds

<= div class=3D"subscribe-widget is-signed-up" data-component-name=3D"Subscrib= eWidget" style=3D"margin: 0 0 1em;direction: ltr;font-size: 16px;line-heigh= t: 26px;">
Upgrade to paid

A Quick Primer on Alzheimer’s

Alzheimer’s i= s defined by two specific things going wrong in the brain:

  1. Amyloid-beta plaq= ues — sticky gunk that builds up between your brain cells. Your body makes a protein called APP and chops i= t into small pieces. In a healthy brain, those pieces get cleared out. In A= lzheimer’s, they clump together into hard plaques that physically blo= ck neurons from communicating.

  2. Tau tangles — tau is a protein that lives inside your neurons and acts like the support beams holding the= cell’s internal scaffolding together. In Alzheimer’s, tau gets= chemically gunked up (a process called “hyperphosphorylation”)= and collapses into twisted tangles inside the cell, which then dies.

Plaques outside the cells, tangles inside the c= ells. Together they’re considered the defining features of Alzheimer&= #8217;s. Reduce either one, and you’re theoretically slowing the dise= ase.

The reason this matters for the study: GLP-1 dru= gs appear to reduce both.

What= The Researchers Did

A team out of Anglia Ruskin Universit= y in the UK did a systematic review — meaning they didn’t run a= new experiment, they pulled together every quality study they could find o= n four specific GLP-1 drugs and looked for patterns:

  • Liraglutide (Saxenda, Victoza)

  • Semaglutide= (Ozempic, Wegovy)

  • Exenatide (Byetta, Bydureon)

  • Dulaglutide (Trulicity)

They searched= PubMed, Embase, and Cochrane Library — the three major medical resea= rch databases. They ended up with 30 preclinical studies (cells in a dish and animal models) and 2 human = clinical trials.

The whole goal: do t= hese drugs actually reduce amyloid plaques and tau tangles? And if so, how?=

What They Found in Animal and Cell Studies

  • 22 out of= 30 studies showed reductions in amyloid-beta plaques=

  • 19 out o= f 30 studies showed reductions in tau tangles

    That’s about 73% showing plaque reduction and 63% = showing tangle reduction. In research terms, that’s a strong, consist= ent signal — not a one-off finding.

    By drug:

    • Liraglutide — the most studied of th= e four. The most consistent. Reduced both plaques AND tangles across multip= le models.

    • Dulaglutide — fewer studies, but consistent. = Reduced both plaques and tangles, and improved cognitive performance in mic= e.

    • Semaglutide — mostly positive. Four studies showed re= ductions, one showed no effect.

    • Exenatide — most mixed r= esults. Some studies showed reductions, others showed nothing. Smallest ove= rall effect.

    How Are GLP-1 Drugs Doing Thi= s? (The Mechanisms)

    This is the most important section. Th= e researchers identified several pathways through which these drugs appear = to fight Alzheimer’s pathology. Walking through them simply:

    1. They calm down brain inflammation

    Your = brain has its own immune cells called microglia. When microglia get stuck i= n “alarm mode” for too long, they pump out inflammatory chemica= ls that actually increase the production of amyloid p= laques. It’s a vicious cycle — inflammation makes plaques, plaq= ues cause more inflammation.

    GLP-1 drugs calm microg= lia down. Less inflammation means less plaque production at the source.

    =

    2. They fix insulin signaling in the brain

    = There’s a reason researchers sometimes call Alzheimer’s “= Type 3 Diabetes.” The Alzheimer’s brain shows insulin resistanc= e — meaning brain cells can’t use sugar for energy properly. Th= at metabolic dysfunction is directly tied to both plaque buildup and tangle= formation.

    GLP-1 drugs were literally designed to fix insu= lin signaling. When they restore that function in brain cells, the brain ge= ts better at clearing out toxic protein waste.

    3. They tu= rn down the enzymes that make plaques

    Remember APP —= the protein that gets chopped up into amyloid fragments? The enzymes doing= the chopping are called secretases. GLP-1 drugs appear to shift the balanc= e away from the “bad” cutting pattern (which produces toxic pla= que material) toward the “safe” cutting pattern (which produces= harmless fragments).

    In other words, they reduce plaque pr= oduction at the factory level.

    4. They block the enzyme t= hat creates tangles

    Tau gets converted into tangles = by an enzyme called GSK-3β. GLP-1 drugs activate a signaling pathway (= called PI3K/Akt) that inhibits GSK-3β.

    Less GSK-3β activity =3D less tau gunking up =3D fewer t= angles forming inside neurons.

    5. They help the brain cle= an itself out

    Your brain has its own waste-clearance syste= m that flushes out toxic proteins. GLP-1 receptors are present on cells cal= led astrocytes that sit around brain blood vessels. When activated, they he= lp move water through the brain in a way that flushes amyloid out.

    Imagine cleaning a room — these drugs aren’t just stopp= ing the mess from getting made, they’re also helping take the trash o= ut.

    6. They help neurons survive in general

    GLP-1 activation increases brain growth factors like BDNF (think of it= as fertilizer for neurons), reduces oxidative stress, supports the cell= 217;s energy production, and prevents premature cell death.

    This is the big-picture takeaway: these drugs aren= 217;t doing one thing. They’re doing six things at once, all in the s= ame direction. That’s a big deal because most failed A= lzheimer’s drugs only targeted one mechanism.

    = The Human Trial Data — Being Honest Here

    This = is where I have to slow the hype train down. The two human clinical trials = in the review were not nearly as impressive as the an= imal data:

    Liraglutide trial (26 weeks):

    • No reduction in plaque burden

    • No improvement in cognition

      • Did preserve brain glucose = metabolism (a sign neurons were still functioning)

  • No signif= icant changes in plaques or tangles in cerebrospinal fluid

  • Did reduce amyloid-beta in extrac= ellular vesicles (an early biomarker)

  • No cognitive benefit

    • S= o: the preclinical data is strong. The human cognitive data = is not there yet.

    My Analysis — What This Ac= tually Means

    A few honest takeaways:

    1. Preclinical-to-human translation is the eternal Alzheimer’s pro= blem. The graveyard of Alzheimer’s drug development is= full of compounds that worked beautifully in mice and failed in humans. Mo= use models are typically genetically engineered to develop pathology fast &= #8212; which doesn’t fully mirror what happens in a human brain over = decades.

    2. The lead author’s framing = is the right one — prevention, not treatment. The rese= archers explicitly say these drugs may work as a preventative, not as a treatment for people who already have established cognit= ive impairment. That tracks with the human trial data — those trials = enrolled people who already had Alzheimer’s. By that point, you may s= imply be too late.

    3. The multi-mechanism st= ory is genuinely promising. Past Alzheimer’s drugs fai= led because they targeted one pathway. GLP-1 drugs hit six at once. That= 217;s a structurally better bet.

    4. There= 217;s a confounder nobody can fully solve yet. GLP-1 drugs t= reat obesity and Type 2 diabetes — two of the biggest modifiable risk= factors for dementia. So are these drugs protecting the brain d= irectly, or are they protecting the brain by treating systemic m= etabolic disease that would otherwise damage the brain? Probably both. The = proportions matter for figuring out who actually benefits most.

    <= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">5. This review only covers the older GLP-1 drugs. Tirzepatide (GLP-1 + GIP) and retatrutide (GLP-1 + GIP + glucagon= ) aren’t in this analysis. Whether the dual and triple agonists carry= a similar — or stronger — neuroprotective signal is still an o= pen question.

    6. The peptide research commun= ity has parallel tools worth knowing. Compounds like Cerebro= lysin, Semax, Selank, and the bioregulators are working on overlapping mech= anisms (inflammation, neurotrophic support, neuronal survival) through diff= erent pathways. The multi-mechanism neuroprotection theme isn’t uniqu= e to GLP-1 drugs — it’s where the entire field is heading.

    Bottom Line

    This review pulls together = strong preclinical evidence that GLP-1 receptor agonists reduce both amyloi= d plaques and tau tangles through multiple mechanisms — inflammation,= insulin signaling, enzyme regulation, brain clearance, and neuroprotection= =2E The signal is consistent and biolo= gically coherent.

    Human= cognitive data isn’t there yet, but that’s likely because the = trials enrolled people too late in the disease. The next wave of trials nee= ds to recruit at-risk people before symptoms start — that’s whe= re the real test happens.

    This is one more data point worth= tracking as the field develops. Stay measured, watch the next 2-3 years of= trial readouts, and don’t get ahead of the evidence.

    Drop questions or thoughts below.

    Discl= aimer: This content is for research and educational purposes only and is no= t medical advice. All compounds discussed (peptides, GLP-1 receptor agonist= s, and related research chemicals) are referenced in the context of researc= h use only (RUO) and the published scientific literature. Nothing in this p= ost should be interpreted as a recommendation for human consumption, diagno= sis, prevention, or treatment of any disease or condition. Always consult a= qualified healthcare professional for medical decisions.

    You're currently a free subscriber to Research Radar. For the full= experience, upgrade your subscription.

    Upgrade to paid

    =
     
    3D""Share
     
     
    3D""Like
    3D""Comment
    <= /td>
    3D""Restack
    		<= tbody>
     

    © 2026 Derek Pruski
    548 Mark= et Street PMB 72296, San Francisco, CA 94104
    Unsubscribe

    3D"Start

    		<= /td>
    =3D""3D"" --106b40a7b3a95666b3da58827db654c5b3602851c7c3f24c927d6d9aba99--